Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene Blue MMX oral tablets for chromoendoscopy DNA safety assessment
2013-000634-35Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lumeblue (2 arms), sponsored by Cosmo Pharmaceuticals. Primary endpoint: Colonic epithelial double-stranded DNA effect. Started Mar 2013; status: completed.
02
Drugs
lumeblue
Beyond the preview
Go deeper on 2013-000634-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000634-35.